The Impact of Radioresistant-Related Telomere Genes in the Prognosis and Immune Infiltration in Lung Adenocarcinoma

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2024 Nov 23

PMID 39580387

Authors

Peng Li

Lu Meng

Hongbin Tu

Shilan Luo

Xiaomei Gong

Affiliations

Soon will be listed here.

Abstract

Introduction: Lung adenocarcinoma (LUAD), a common subtype of NSCLC, has a high mortality rate. Telomere genes are influenced by radiation therapy, affecting treatment response. Additionally, immune cell presence in the tumor microenvironment plays a crucial role in cancer prognosis. However, the role of Radioresistant-Related Telomere Genes (RRTGs) in LUAD prognosis and immune infiltration remains unclear.

Methods: In this research, we utilized diverse bioinformatics techniques to examine our personally tested information along with publicly accessible datasets. We conducted a comprehensive study on the genetic and transcriptional differences, predictive significance, and expression profiles of RRTGs. Afterwards, a RRTGs score was developed to forecast the overall survival (OS) and ascertain its reliable predictive capacity for patients with LUAD. Following this, dependable nomograms were developed to enhance the practicality of RRTGs scoring in a clinical setting. Furthermore, the investigation delved into the associations among RRTGs, infiltration of immune cells, prognosis, and clinical treatments of patients. Gene Set Enrichment Analysis (GSEA) was conducted to explore the potential mechanisms by which RRTGs influence the regulation of LUAD. Then, Western blot, qRT-PCR and Immunohistochemistry were used to detect the expression levels of RRTGs in cell lines and LUAD tumor tissues.

Results: Our research indicates that certain genes related to telomeres have a notable correlation with the prognosis of patients diagnosed with LUAD. The RRTGs score, which includes three key genes (ARRB1, PLK1, and DSG2), was developed to forecast the OS and its dependable predictive capability for individuals diagnosed with LUAD was ascertained. Afterwards, extremely reliable nomograms were developed to improve the practicality of the RRTGs score. Moreover, as illustrated, genetic characteristics can be utilized to assess the infiltration of immune cells in tumors, as well as clinical attributes and prognosis. RRTGs score characterizes tumor mutational burden, immune activity, and notable survival probabilities in addition. Furthermore, GSEA results revealed that RRTGs may influence LUAD by modulating immune-related pathways in high-risk groups and regulating cell cycle and DNA repair processes in low-risk groups. The RRTGs (ARRB1 and PLK1) were upregulated in A549 cells and radiosensitive NSCLC tissues compared to radioresistant A549 cells and NSCLC tissues.

Conclusion: In conclusion, this research emphasizes the significance of RRTGs in the outlook of LUAD. The findings contributed to a better understanding of the link between radiotherapy, telomere-related genes, and prognosis in LUAD, and identified potential therapeutic targets for patients with LUAD.

References

Leek J, Johnson W, Parker H, Jaffe A, Storey J . The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28(6):882-3. PMC: 3307112. DOI: 10.1093/bioinformatics/bts034. View

Kang L, Miao M, Song Y, Fang X, Zhang J, Zhang Y . Total flavonoids of Taraxacum mongolicum inhibit non-small cell lung cancer by regulating immune function. J Ethnopharmacol. 2021; 281:114514. DOI: 10.1016/j.jep.2021.114514. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Krisnawan V, Stanley J, Schwarz J, DeNardo D . Tumor Microenvironment as a Regulator of Radiation Therapy: New Insights into Stromal-Mediated Radioresistance. Cancers (Basel). 2020; 12(10). PMC: 7600316. DOI: 10.3390/cancers12102916. View

Sun H, Liu S, Zhou J, Xu J, Zhang H, Yan H . Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. EBioMedicine. 2020; 60:102990. PMC: 7494676. DOI: 10.1016/j.ebiom.2020.102990. View

Ebata H, Loo T, Takahashi A . Telomere Maintenance and the cGAS-STING Pathway in Cancer. Cells. 2022; 11(12). PMC: 9221635. DOI: 10.3390/cells11121958. View

Chen F, Huang C, Wu Q, Jiang L, Chen S, Chen L . Circular RNAs expression profiles in plasma exosomes from early-stage lung adenocarcinoma and the potential biomarkers. J Cell Biochem. 2019; 121(3):2525-2533. DOI: 10.1002/jcb.29475. View

10.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

11.

Hu K, Zhao L, Feng S, Zhang S, Zhou Q, Gao X . Colorectal polyp region extraction using saliency detection network with neutrosophic enhancement. Comput Biol Med. 2022; 147:105760. DOI: 10.1016/j.compbiomed.2022.105760. View

12.

Shay J, Wright W . Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov. 2006; 5(7):577-84. DOI: 10.1038/nrd2081. View

13.

Allibhai Z, Taremi M, Bezjak A, Brade A, Hope A, Sun A . The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013; 87(5):1064-70. DOI: 10.1016/j.ijrobp.2013.08.020. View

14.

Zhang H, Zhou F, Wang Y, Xie H, Luo S, Meng L . Eliminating Radiation Resistance of Non-Small Cell Lung Cancer by Dihydroartemisinin Through Abrogating Immunity Escaping and Promoting Radiation Sensitivity by Inhibiting PD-L1 Expression. Front Oncol. 2020; 10:595466. PMC: 7656009. DOI: 10.3389/fonc.2020.595466. View

15.

Chen D, Wang Y, Zhang X, Ding Q, Wang X, Xue Y . Characterization of Tumor Microenvironment in Lung Adenocarcinoma Identifies Immune Signatures to Predict Clinical Outcomes and Therapeutic Responses. Front Oncol. 2021; 11:581030. PMC: 7973234. DOI: 10.3389/fonc.2021.581030. View

16.

Johnson W, Li C, Rabinovic A . Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2006; 8(1):118-27. DOI: 10.1093/biostatistics/kxj037. View

17.

Wang L, Wang K, Dong W, Shen H, Du J . Regulation of response to radiotherapy by β-arrestin1 in Non-small cell lung cancer. J Cancer. 2019; 10(17):4085-4095. PMC: 6692618. DOI: 10.7150/jca.30012. View

18.

Berardinelli F, Coluzzi E, Sgura A, Antoccia A . Targeting telomerase and telomeres to enhance ionizing radiation effects in in vitro and in vivo cancer models. Mutat Res Rev Mutat Res. 2017; 773:204-219. DOI: 10.1016/j.mrrev.2017.02.004. View

19.

Jin Z, Guan L, Xiang G, Gao B . Radiation resistance of the lung adenocarcinoma is related to the AKT-Onzin-POU5F1 axis. Biochem Biophys Res Commun. 2018; 499(3):538-543. DOI: 10.1016/j.bbrc.2018.03.185. View

20.

Wu G, Yan Y, Cai Y, Peng B, Li J, Huang J . ALKBH1-8 and FTO: Potential Therapeutic Targets and Prognostic Biomarkers in Lung Adenocarcinoma Pathogenesis. Front Cell Dev Biol. 2021; 9:633927. PMC: 8209387. DOI: 10.3389/fcell.2021.633927. View